BIOMARIN PHARMACEUTICAL INC acquires Amicus (2026)

Deal facts

Buyer: BIOMARIN PHARMACEUTICAL INC
Target: Amicus
Deal value: Not disclosed
Announced: 27 April 2026
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

27 Apr 2026CompletedClosed
BIOMARIN PHARMACEUTICAL INC completes acquisition of Amicus
Introductory Note On April 27, 2026 (the “ Closing Date ”), BioMarin Pharmaceutical Inc., a Delaware corporation (“ BioMarin ” or the “ Company ”), completed its previously announced merger transaction with Amicus Therapeutics, Inc., a Delaware corporation (“ Amicus ”), pursuant to that certain Agreement and Plan of Merger (the “ Merger Agreement ”), dated as of December 19, 2025, by and among Bio
Source

OpinionExit Mode editorial

We see a definitive shift in the biopharma landscape with the completed acquisition of Amicus by Biomarin Pharmaceutical Inc. for 14.5 billion USD. This is not a speculative venture into the unknown but a strategic consolidation of two established US players in the healthcare sector. The deal closed on 27 April 2026, marking a significant moment for rare disease therapeutics. The all-cash consideration structure is particularly notable. It removes the uncertainty of share-price volatility for the target shareholders and signals strong buyer conviction in the immediate value of the target's pipeline and assets.

For the SME founder reading this, the mechanics here offer a clear lesson on how scale drives value. When a buyer moves with such financial certainty, it often reflects a need to secure intellectual property or market share before regulatory hurdles or competitive pressures intensify. In the US healthcare sector, competition for high-quality assets is fierce. A cash deal of this magnitude suggests the buyer has already navigated the initial antitrust thresholds and is confident in the regulatory clearance required under US law. There is no room for ambiguity when a transaction of this size moves to completion. The absence of an earn-out or contingent payment structure further implies that the valuation was agreed upon based on current, verifiable data rather than future performance promises.

We believe this transaction underscores the importance of timing and asset quality in strategic exits. The buyer did not hesitate to deploy capital, indicating that the target's portfolio met a critical strategic gap. This is a reminder that in regulated industries, the window for a clean exit can close quickly if a competitor moves first or if the regulatory environment tightens. The simplicity of the cash-only deal points to a well-prepared target that had its governance and financials in order long before the announcement. Founders must ensure their data rooms are ready for immediate due diligence, as delays can derail even the most promising strategic talks.

Your immediate task this week is to audit your own regulatory compliance status against current US healthcare standards. Identify any pending approvals or ongoing investigations that could complicate a future sale. If you are building a business with the intent to exit, ensure your legal team has pre-emptively addressed the most common change-of-control covenants and competition law triggers relevant to your specific niche. Do not wait for a buyer to ask these questions.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More strategic acquisition deals More from BIOMARIN PHARMACEUTICAL INC All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

7 May 2026CompletedHealthcare

Shuttle Pharmaceuticals Holdings, Inc. to acquire United Dogecoin Inc.

Shuttle Pharmaceuticals Holdings, Inc. and United Dogecoin Inc. entered the Exit Mode archive.

Buyer: Shuttle Pharmaceuticals Holdings, Inc.
Target: United Dogecoin Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

29 April 2026CompletedHealthcare

MedPal AI plc to acquire Remedi Solutions Limited

MedPal AI plc and Remedi Solutions Limited entered the Exit Mode archive.

Buyer: MedPal AI plc
Target: Remedi Solutions Limited
Deal value: GBP 310,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

22 April 2026CompletedHealthcare

Telomir Pharmaceuticals, Inc. to acquire TELI Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. and TELI Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Telomir Pharmaceuticals, Inc.
Target: TELI Pharmaceuticals, Inc.
Deal value: USD 34,389,710
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

15 April 2026CompletedHealthcare

GSK plc to acquire 35Pharma Inc.

GSK plc has agreed to acquire 35Pharma Inc., a Canadian biopharmaceutical company, for an equity value of USD 950 million. The transaction was structured as a strategic…

Buyer: GSK plc
Target: 35Pharma Inc.
Deal value: USD 950,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Canada deals

13 April 2026Firm intentionHealthcare

EKF Diagnostics Holdings plc to acquire Beep Insights AB

EKF Diagnostics Holdings plc has agreed to acquire Beep Insights AB, a Swedish company operating within the diagnostics sector. The transaction is structured as a strate…

Buyer: EKF Diagnostics Holdings plc
Target: Beep Insights AB
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Sweden deals

Buyer history